IMCDIMCD
IMCD logo
Fair Value
€116.57
Share price07 Aug
€95.4618.1% undervalued intrinsic discount
Loading
1Y2.18%
7D-1.61%

IMCD: Share Price Pullback Will Offer Attractive Entry As Ratings Improve

Analyst Consensus Target compiles analysts opinions to create narratives on stocks using the Analysts Consensus Price Target, forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published
25 Nov 24
Updated
07 Aug 26
Views
172
Not Invested

Last Update 07 Aug 26

Fair value Increased 3.62%

IMCD: Global Expansion And Margin Strength Will Support Future Upside

The updated analyst price target for IMCD moves from about €112.50 to roughly €116.60, as analysts weigh slightly lower revenue growth expectations against firmer profit margin assumptions, together with a mixed set of recent price target and rating changes from major banks.

Analyst Commentary

Recent research on IMCD shows a split between bullish analysts who focus on earnings potential and valuation support, and bearish analysts who are more cautious about the earnings outlook and sector headwinds.

Bullish Takeaways

  • Bullish analysts highlight earnings growth potential for IMCD, which they see as supportive of higher long term value if the company delivers on profit expectations.
  • Several bullish views come with higher price targets in the €100 to €123 range, which signals confidence that the current share price does not fully reflect IMCD's execution potential.
  • Some research points to improving conditions for IMCD that could support more resilient profitability, which investors may view as helpful for valuation stability.
  • The combination of higher targets and positive ratings suggests bullish analysts are comfortable with IMCD's balance between growth opportunities and current pricing.

Bearish Takeaways

  • JPMorgan takes a more cautious stance with an Underweight rating and a €75 price target, which sits well below the more optimistic targets from other firms.
  • Bearish analysts flag an uncertain mid term earnings outlook for IMCD, and expect earnings to sit well below existing consensus forecasts.
  • Concerns include both structural and cyclical headwinds for the wider European chemicals space, which could limit IMCD's ability to convert revenue into consistent profit growth.
  • JPMorgan also points to less attractive valuation compared with other stocks in its coverage and sees the recent earnings tailwind from the Middle East conflict as fading, which would reduce a temporary source of support.

What’s in the News for IMCD

  • IMCD reported EBITA of €285 million in the first half of 2026, with the company highlighting organic growth in gross profit and EBITA, along with higher free cash flow generation. Source: IMCD first half 2026 results.
  • The company completed the acquisitions of Dong Yang FT in South Korea and Willows Ingredients in Ireland and the UK, which expand IMCD’s presence in these markets. Source: IMCD first half 2026 results.
  • IMCD signed an agreement to acquire Merit Solution in Thailand, adding to its pipeline of recent deals. Source: IMCD first half 2026 results.
  • Management, led by CEO Marcus Jordan, reiterated a focus on long term partnerships and on commercial, operational and digital excellence to support value creation for stakeholders. Source: IMCD first half 2026 results.
  • Michelin ResiCare appointed IMCD Europe as distributor for its bio based 5 HMF across Europe ahead of commercial production planned for 2027, with IMCD set to provide logistics and local technical support for this renewable platform chemical. Source: Michelin ResiCare and IMCD distribution agreement.

Valuation Changes for IMCD

Recent updates to the IMCD model show several small but meaningful shifts in key valuation inputs. These changes give you a clearer view of how analysts are framing risk, growth and profitability for the stock.

  • Fair Value has risen slightly from €112.50 to about €116.60, which reflects the latest balance of updated assumptions for IMCD.
  • Discount Rate is marginally higher, moving from 7.16% to about 7.29%, which points to a slightly stronger required return for IMCD in the updated model.
  • Revenue Growth has edged lower, moving from about 5.24% to roughly 4.86%, which indicates a more cautious view on future € revenue expansion for IMCD.
  • Net Profit Margin has risen from about 5.36% to roughly 5.95%, which signals a modestly stronger expected earnings contribution on each € of revenue.
  • Future P/E has moved lower from about 27.2x to roughly 24.9x, which implies a reduced valuation multiple applied to IMCD's forward earnings in the updated assumptions.
3 viewsusers have viewed this narrative update

Key Takeaways

  • Expansion into resilient end-markets and digitalization enhances operational efficiency, customer loyalty, and positions IMCD for sustained revenue and margin growth.
  • Differentiated specialty offerings and industry outsourcing trends support long-term growth, while short-term disruptions are expected to ease as integration and diversification efforts bear fruit.
  • Currency volatility, weak organic growth, high acquisition risks, and mounting competitive pressures threaten margins, cash flow, and IMCD's ability to sustain long-term profitability.

Catalysts

About IMCD
    Distributes, markets, and sells specialty chemicals and ingredients in the Netherlands, rest of Europe, the Middle East, Africa, North America, South America, and the Asia-Pacific.
What are the underlying business or industry changes driving this perspective?
  • IMCD's strategic expansion into high-growth and resilient end-markets (pharma, food & nutrition, personal care) through both organic efforts and targeted M&A increases exposure to industries with strong, recurring demand fundamentals-which can support sustainable revenue and margin expansion as macro uncertainty fades.
  • The company's ongoing investment in digitalization (e.g. sales assistant tool, omnichannel strategy) is expected to drive greater operational efficiency, customer stickiness, and scalability, potentially leading to improved cost structure and higher net margins over the medium to long term.
  • Increased focus by manufacturers on outsourcing sales, marketing, and distribution functions continues to favor specialized third-party distributors like IMCD, which supports long-term revenue growth as industry outsourcing trends deepen.
  • Heightened customer and regulatory demands for innovation, sustainability, and technical expertise position IMCD's differentiated specialty portfolio as a key supplier across industries adopting greener, more complex formulations; this should underwrite above-market growth and gross margin resilience.
  • Recent customer order delays, elevated inventories, and FX headwinds have temporarily dampened reported results and cash flow, but the underlying market share gains, geographic diversification, and multi-region M&A integration efforts set the stage for strong earnings rebound and cash generation as short-term disruptions normalize.
IMCD Earnings and Revenue Growth

IMCD Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

  • Analysts are assuming IMCD's revenue will grow by 4.9% annually over the next 3 years.
  • Analysts assume that profit margins will increase from 4.6% today to 6.0% in 3 years time.
  • Analysts expect earnings to reach €341.0 million (and earnings per share of €5.75) by about August 2029, up from €230.2 million today. However, there is some disagreement amongst the analysts with the more bearish ones expecting earnings as low as €291.4 million.
  • In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 24.9x on those 2029 earnings, down from 25.8x today. This future PE is lower than the current PE for the GB Trade Distributors industry at 25.8x.
  • Analysts expect the number of shares outstanding to remain consistent over the next 3 years.
  • To value all of this in today's terms, we will use a discount rate of 7.29%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?
  • Volatile foreign exchange rates, particularly the weakening of the U.S. dollar and Indian rupee, have negatively impacted revenue and EBITDA, with management indicating continuing currency headwinds could further suppress reported financials and profit margins.
  • Persistent macroeconomic uncertainty and tariff-related disruptions are leading IMCD's customers to delay orders and refrain from commitments, resulting in elevated inventory, increased working capital requirements, and risk to near-term and potentially longer-term revenue recognition and cash flow.
  • Organic revenue and EBITA growth are modest, with recent quarters showing flat or declining trends; inflation-driven cost increases, especially in personnel, are outpacing organic growth and causing conversion margins and net profits to decline, highlighting difficulty in offsetting fixed cost growth without stronger demand recovery.
  • Heightened M&A pace and reliance on acquisitions for growth expose IMCD to risks of overpaying for targets and integration challenges, as shown by rising amortization and financing costs linked to acquisition-related intangibles and deferred considerations, which could weigh on net margins and cash generation.
  • Increased competition from local players in regions like China, as well as pricing pressures in more commoditized segments, could reduce IMCD's pricing power and market share, contributing to long-term gross margin compression and risking a structural shift in profitability if these trends persist.

Valuation

How have all the factors above been brought together to estimate a fair value?

  • The analysts have a consensus price target of €116.57 for IMCD based on their expectations of its future earnings growth, profit margins and other risk factors.
  • However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of €150.0, and the most bearish reporting a price target of just €75.0.
  • In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be €5.7 billion, earnings will come to €341.0 million, and it would be trading on a PE ratio of 24.9x, assuming you use a discount rate of 7.3%.
  • Given the current share price of €100.75, the analyst price target of €116.57 is 13.6% higher.
  • We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on IMCD?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Comments

0 comments

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Read more narratives

Fair Value vs Share Price

€116.57
vs €95.4618.1% undervalued intrinsic discount
PastFuture06b2015201820212024202620272029Revenue €5.7bEarnings €341.0m
4.9%
Revenue growth
6%
Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on IMCD

  • Fair value estimate changes
  • Narrative and analyst updates
  • Key company announcements

Company analysis

Adequate balance sheet average dividend payer.

Market cap€5.6b
PB2.7x
Estimated Growth4.9%
Dividend Yield1.9%
Full analysis

CEO & management

Marcus Jordan
CEO
2.1yrs
CEO Tenure

Distributes, markets, and sells specialty chemicals and ingredients in the Netherlands, rest of Europe, the Middle East, Africa, North America, South America, and the Asia-Pacific.